TD-106 structure
|
Common Name | TD-106 | ||
---|---|---|---|---|
CAS Number | 2250288-69-6 | Molecular Weight | 273.25 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C12H11N5O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of TD-106TD-106 is a cereblon (CRBN) modulator, which can be used for targeted protein degradation. BRD4 PROTACs with TD-106 induce BRD4 degradation[1]. |
Name | TD-106 |
---|
Description | TD-106 is a cereblon (CRBN) modulator, which can be used for targeted protein degradation. BRD4 PROTACs with TD-106 induce BRD4 degradation[1]. |
---|---|
Related Catalog | |
Target |
CRBN[1] |
In Vitro | TD-106 (0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, 10 μM, and 100 μM; 72 hours) inhibits the proliferation of NCI-H929 myeloma cell line with an CC50 of 0.039 μM[1]. TD-106 (1, 10, 100, and 1000 nM) induces the degradation of IKZF1/3 in NCI-H929 cells[1]. Cell Cytotoxicity Assay[1] Cell Line: NCI-H929 cells Concentration: 72 hours Incubation Time: 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, 10 μM, and 100 μM Result: Inhibited cell proliferation with an CC50 of 0.039 μM. |
In Vivo | TD-106 (50 mg/kg; intraperitoneally; q.d. for 14 days) possesses anti-myeloma activity in SCID mice with TMD-8 xenograft model. Animal Model: Female SCID (CB-17/IcrCri-scid) mice with TMD-8 xenograft model[1] Dosage: 50 mg/kg Administration: Intraperitoneally (i.p.); q.d. for 14 days Result: Treatment inhibited tumor growth during this duration. |
References |
Molecular Formula | C12H11N5O3 |
---|---|
Molecular Weight | 273.25 |
Storage condition | 2-8℃ |